Posted by Michael Wonder on 10 Jul 2022
SIGA Technologies receives approval from UK for tecovirimat
8 July 2022 - Treatment approved for smallpox, monkeypox, cowpox and vaccinia complications.
SIGA Technologies today announced that the United Kingdom has approved SIGA’s oral tecovirimat (known in the U.S. as oral TPOXX) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox in adults and children with a body weight of at least 13 kg.
